Compare FSV & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSV | TVTX |
|---|---|---|
| Founded | 1988 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.3B |
| IPO Year | 2015 | 2013 |
| Metric | FSV | TVTX |
|---|---|---|
| Price | $128.44 | $57.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 15 |
| Target Price | ★ $173.88 | $75.21 |
| AVG Volume (30 Days) | 170.4K | ★ 1.3M |
| Earning Date | 10-22-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.24 | $47.65 |
| Revenue Next Year | $5.85 | $49.39 |
| P/E Ratio | $49.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $119.41 | $22.59 |
| 52 Week High | $190.11 | $68.73 |
| Indicator | FSV | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 41.15 |
| Support Level | $122.19 | $58.32 |
| Resistance Level | $146.14 | $59.93 |
| Average True Range (ATR) | 3.36 | 2.32 |
| MACD | -0.19 | -0.61 |
| Stochastic Oscillator | 25.15 | 17.62 |
FirstService Corp is engaged in outsourcing property services. The company operates in two business divisions: FirstService Residential and FirstService Brands. FirstService Residential has service contracts to manage thousands of residential communities, including high and low-rise condominiums and co-operatives. FirstService Brands generates the majority of the company's revenue and provides property services to residential and commercial customers through the following brands: California Closets; Paul Davis Restoration; CertaPro Painters, Floor Coverings International, and Pillar to Post Home Inspectors. The company earns the majority of its revenue in the United States, with the remaining revenue generated in Canada.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.